Table 1 Reported HR for PFS and OS and severe AEs rate of each eligible study
Study | Study | Control | HR for PFS | HR for OS | Severe AEs rate, % |
|---|---|---|---|---|---|
PALOMA-1 | P + AI | AI | 0.488 (0.319, 0.748) | 0.9897 (0.623, 1.294) | 75.90 vs. 20.78 |
PALOMA-2 | P + AI | AI | 0.563 (0.461, 0.687) | n.r. | 79.28 vs. 28.38 |
PALOMA-3 | P + F | F | 0.50 (0.40, 0.62) | 0.81 (0.64, 1.03) | 72.33 vs. 21.84 |
MONALEESA-2 | R + AI | AI | 0.568 (0.457, 0.704) | 0.746 (0.517, 1.078) | 82.04 vs. 32.73 |
MONALEESA-3 | R + F | F | 0.593 (0.480, 0.732) | 0.73 (0.59, 0.90) | 28.51 vs. 16.53 |
MONALEESA-7 | R + AI | AI | 0.55 (0.44, 0.69) | 0.71 (0.54, 0.95) | 82.09 vs. 29.67 |
MONARCH-2 | A + F | F | 0.553 (0.449, 0.681) | 0.757 (0.606, 0.945) | 65.99 vs. 26.91 |
MONARCH-3 | A + AI | AI | 0.540 (0.418, 0.698) | n.r. | 58.41 vs. 24.84 |
MONARCH plus (cohort A) | A + AI | AI | 0.499 (0.346, 0.719) | n.r. | 59.02 vs. 23.23 |
MONARCH plus (cohort B) | A + F | F | 0.376 (0.240, 0.588) | n.r. | 51.92 vs. 15.09 |